https://orcid.org/0000-0001-9072-2303
References
- Alvarez FP, Chevalier P, Borms M, et al. Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal. J Med Econ. 2023;26(1):710–719. doi: 10.1080/13696998.2023.2194193.
- DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645. doi: 10.1056/NEJMoa1315727.
- Lee JK, Lam GK, Vaisman R, et al. 102. Efficacy and effectiveness of high-dose influenza vaccine in older adults by age and seasonal characteristics: an updated systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(Supplement_2):A24–A35. doi: 10.1093/ofid/ofac492.180.
- Somes MP, Turner RM, Dwyer LJ, et al. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: a systematic review and meta-analysis. Vaccine. 2018;36(23):3199–3207. doi: 10.1016/j.vaccine.2018.04.063.
- Yin JK, Pepin S, van Aalst R, et al. Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years. Hum Vaccin Immunother. 2022;18(6):2106749.
- Tokars JI, Olsen SJ, Reed C. Seasonal incidence of symptomatic influenza in the United States. Clin Infect Dis. 2018;66(10):1511–1518. doi: 10.1093/cid/cix1060.